Table 3 The patients’ characteristics at transplantation according to myelofibrosis (n = 141)
|  | MF = 0/1 (n = 121) | MF = 2/3 (n = 20) | P |
|---|---|---|---|
Median age of recipient at HSCT (range) | 44 (18–66) | 42 (27–60) | 0.747 |
Recipient sex | 0.511 | ||
 Male | 70 (57.9%) | 10 (50.0%) |  |
 Female | 51 (42.1%) | 10 (50.0%) |  |
Recipient cytogenetic | 0.743 | ||
 Non-complex karyotypes | 102 (84.3%) | 16 (80.0%) |  |
 Complex karyotypes | 19 (15.7%) | 4 (20.0%) |  |
BM blasts at HSCT | 0.016 | ||
  ≤ 5% | 29 (24.0%) | 10 (50.0%) |  |
  > 5% | 92 (76.0%) | 10 (50.0%) |  |
Time to HSCT from diagnosis | 0.529 | ||
  ≤ 6 months | 87 (71.9%) | 13 (65.0%) |  |
 > 6 months | 34 (28.1%) | 7 (35.0%) |  |
Previous therapy for MDS | 0.861 | ||
 No cytoreductive treatments | 57 (47.1%) | 9 (45.0%) |  |
 Cytoreductive treatments | 64 (52.9%) | 11 (55.0%) |  |
  HMA | 27 (22.3%) | 4 (20.0%) |  |
  Chemotherapy combined with HMA | 34 (28.1%) | 7 (35%) |  |
  AML-like chemotherapy | 3 (2.5%) | 0 (0.0%) |  |
 Median age of donor (range) | 37 (10–63) | 40 (26–60) | 0.181 |
Donor sex | 0.323 | ||
 Male | 77 (63.6%) | 15 (75.0%) |  |
 Female | 44 (34.2%) | 5 (25.0%) |  |
Donor source | 0.838 | ||
 HID | 51 (42.1%) | 8 (40%) |  |
 MUD | 10 (8.3%) | 1 (5%) |  |
 MSD | 60 (49.6%) | 11 (55%) |  |
Stem cell source | 0.605 | ||
 PB | 62 (51.2%) | 9 (45.0%) |  |
 PB + BM | 59 (48.8%) | 11 (55.0%) |  |
Median mononuclear cells per graft × 108/kg, (range) | 10.2 (7.21–13.9) | 10.4 (8.3–14.0) | 0.479 |
Median CD34 + cells per graft × 106/kg, (range) | 9.5 (6.8–13.1) | 9.8 (8.1–13.7) | 0.246 |
Conditioning regimens | 0.051 | ||
 BUCY | 56 (46.3%) | 3 (15.0%) |  |
 DAC + BUCY | 48 (39.7%) | 13 (65.0%) |  |
 BUCY + others | 9 (7.4%) | 3 (15.0%) |  |
 BF | 8 (6.6%) | 1 (5.0%) |  |
GVHD prophylaxis | 0.870 | ||
 CsA + MTX + MMF | 60 (49.6%) | 11 (55.0%) |  |
 CsA + MTX + ATG | 5 (4.1%) | 1 (5.0%) |  |
 CsA + MTX + ATG + MMF | 56 (46.3%) | 8 (40.0%) |  |